Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting — Clinical trial initiated in February 2019 in the U.S.,MD Anderson Cancer Center and Sarah Cannon Research Institute — Phase...
ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 myeloid checkpoint mechanism, today announced new results from its Phase 1 ALX148 solid tumor program at the 2019 ASCO Annual Meeting [ Abstract #2514 ]. As of April 18,...
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that the Stanford University School of Medicine will serve as the second contracted...
Follow-Up Data From The Phase I Trial Of DCVax®-Direct, and Progress Report On The Road To Unblinding The DCVax®-L Phase III GBM Trial Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid...
Poster presentation tomorrow, June 1st at 8:00 am CT in Poster Hall A Conference call and webcast to discuss results Monday, June 3rd at 8:30 am ET CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical...
Interim results of a large, multicenter trial to be presented at ASCO Annual Meeting For patients with operable non-small cell lung cancer (NSCLC), pre-surgical “neoadjuvant” treatment with an immune checkpoint inhibitor was well tolerated and, in many...
Email
Text